NEW YORK, Dec. 3 – French genomics company ExonHit Therapeutics said Monday it raised 30 million euros ($26.8 million) in a third round of private financing.

The Paris-based company, which develops therapeutics and diagnostics based on the analysis of alternative splicing events, said that Dresdner Kleinwort Capital of the UK, Danske Bank of Denmark, and France’s LCF E. de Rothschild and Sudinnova participated in the financing round. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.